A short course of immunotherapy was found to be highly effective in a subset of patients with colon cancer. The treatment, which consisted of two cycles of immunotherapy prior to surgery, was effective in almost all patients. In two-thirds of patients, there were no longer any live tumor cells at the time of surgery. The patients' immune systems had cleaned up the cancer cells. These discoveries were made as part of the NICHE-2 trial. Patients with colon cancer with a specific genetic makeup, known as mismatch-repair deficient (dMMR) or microsatellite instable (MSI), were treated with one cycle of ipilimumab and...